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Evaluations of vaccine effectiveness (VE) are important to
monitor as coronavirus disease 2019 (COVID-19) vaccines are
introduced in the general population. Research staff enrolled
symptomatic participants seeking outpatient medical care for
COVID-19–like illness or severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) testing from a multisite network.
VE was evaluated using the test-negative design. Among 236
SARS-CoV-2 nucleic acid amplification test-positive and 576
test-negative participants aged ≥16 years, the VE of messenger
RNA vaccines against COVID-19 was 91% (95% confidence interval, 83%–95%) for full vaccination and 75% (55%–87%) for
partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient
medical care.
Keywords: SARS-CoV-2; COVID-19; vaccine effectiveness.
Randomized controlled trials and real-world effectiveness
studies have demonstrated high coronavirus disease 2019
(COVID-19) vaccine effectiveness (VE) against severe outcomes
and symptomatic illness among priority groups for vaccination,
including healthcare workers and persons aged ≥65 years [1–5].
Following the Advisory Committee on Immunization Practice’s
recommendations for COVID-19 vaccine allocation to target
populations, states expanded vaccine availability to the general

Received 20 July 2021; editorial decision 2 September 2021; accepted 7 September 2021;
published online September 8, 2021.
Correspondence: Sara S. Kim, Influenza Division, Centers for Disease Control and Prevention,
1600 Clifton Rd NE, Mailstop 24/7, Atlanta, GA 30329 (skim10@cdc.gov).
The Journal of Infectious Diseases®  2021;XX:1–5
Published by Oxford University Press for the Infectious Diseases Society of America 2021.
This work is written by (a) US Government employee(s) and is in the public domain in the US.
https://doi.org/10.1093/infdis/jiab451

public aged ≥16 years starting in the spring of 2021 [6]. Given
the more common clinical presentation of mild to moderate illness compared to severe outcomes, data are needed on VE for
the prevention of COVID-19 among persons seeking care for
COVID-19–like illness (CLI) in outpatient settings [7].
Since 2008, the US Influenza Vaccine Effectiveness Network
(US Flu VE Network) has provided influenza VE estimates annually. The strength of this long-standing active surveillance
network includes coupling of clinical and epidemiological data
in thousands of patients annually to generate VE estimates
midway through each influenza season. These estimates provide
decision makers with real-time data to assess VE in the current season and contribute to informing global annual vaccine
strain selection decisions. Investigations of VE in outpatient
settings can enhance our understanding of protection among
persons seeking care for mild or moderate illness, contribute to
estimating the averted healthcare burden attributed to COVID19, and inform community mitigation policies as vaccine coverage continues to increase among adults and adolescents in
the United States. We used the robust surveillance platform
of the US Flu VE Network to estimate VE against laboratoryconfirmed severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection among persons aged ≥16 years with
COVID-19–like symptoms seeking outpatient care or clinical
SARS-CoV-2 testing.
METHODS

We used the test-negative design to evaluate messenger RNA
(mRNA) VE against outpatient COVID-19 by comparing vaccine receipt in persons testing positive or negative for SARSCoV-2 infection [8]. Beginning in March 2020, participating
health systems offering outpatient medical care at 5 study sites
for the US Flu VE Network in Michigan, Pennsylvania, Texas,
Washington, and Wisconsin began active surveillance for
COVID-19.
Research staff screened persons who sought outpatient
medical care (ie, telehealth, primary care, urgent care, and
emergency departments) or clinical SARS-CoV-2 testing
using a standard case definition for CLI of an acute onset
of fever or feverishness, cough, or loss of taste or smell with
symptom duration <10 days [9]. Research staff contacted
potentially eligible outpatients by telephone or electronic
message to confirm eligibility and enroll consenting participants. In addition to meeting the CLI definition, eligible
participants had a clinical or research respiratory specimen
collected for SARS-CoV-2 molecular testing within 10 days
of illness onset. Standardized questionnaires collected demographic information, general health status, self-reported
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RESULTS

Between 1 February and 28 May 2021, 27% of outpatients who
were contacted for screening and enrollment agreed to participate. Among 812 enrolled participants aged ≥16 years with CLI,
236 (29%) tested positive for SARS-CoV-2. During the study
period, 36 positive SARS-CoV-2 specimens from the US Flu
VE Network were sequenced, of which 56% were identified as
the alpha (B.1.1.7) variant. SARS-CoV-2 positivity was higher
among male participants, those identifying as non-Hispanic
black, those aged <65 years, and participants enrolled from
the Michigan and Pennsylvania study sites (Table 1). Within
the enrollment period, SARS-CoV-2 positivity peaked during the
second week of April.
Across all vaccinated participants included in the analysis,
226 (62%) received Pfizer-BioNTech, and 138 (38%) received
the Moderna vaccine. Among the 236 SARS-CoV-2–positive
case patients, 37 (16%) received ≥1 dose of an mRNA COVID19 vaccine (Table 2). Seventeen (46%) of the 37 case patients
who received any vaccine dose were considered fully vaccinated, of whom 15 received Pfizer-BioNTech and 2 received
Moderna; 20 (54%) of the 37 were partially vaccinated, of whom
15 received Pfizer-BioNTech and 5 received Moderna. In comparison, 327 (57%) SARS-CoV-2–negative controls were vaccinated with ≥1 dose, of whom 231 (71%) were fully vaccinated
and 96 (29%) were partially vaccinated (Table 2).
The effectiveness of mRNA vaccines against laboratoryconfirmed COVID-19 in outpatient settings was 91% (95%
confidence interval, 83%–95%) among fully vaccinated and
75% (55%–87%) among partially vaccinated participants (Table
2). VE was similar when using documentation, plausible self-report, or both to classify vaccination status (Supplementary
Table 2). In addition, VE including participants who received
the Johnson & Johnson’s Janssen vaccine was similar to that of
mRNA vaccines.
DISCUSSION

During February–May 2021 when the alpha (B.1.1.7) variant
was the predominant circulating strain in the United States,
vaccination reduced laboratory-confirmed symptomatic illness
by 91% among those fully vaccinated and 75% among those
partially vaccinated in a multisite outpatient network evaluating
COVID-19 VE [10]. These findings add to evidence from clinical trials of efficacy against symptomatic illness and observational studies of VE across the continuum of illness severity in
multiple countries [1–5, 11–13].
Monitoring VE against COVID-19 in outpatient settings
is relevant for 3 reasons. First, outpatient settings may better
capture younger age groups, which account for an increasing
proportion of COVID-19 cases and are likely to present with
moderate symptoms, necessitating outpatient care rather than
hospitalization [14]. Furthermore, vaccine coverage is lower in
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COVID-19 vaccination, and history of individual respiratory, gastrointestinal, and systemic symptoms experienced
during acute illness, as well as potential risk factors for contracting COVID-19, such as working in a healthcare setting
and having contact with a person with laboratory-confirmed
COVID-19. SARS-CoV-2 nucleic acid amplification test results were used to classify SARS-CoV-2–positive cases and
test-negative controls. Research testing, or testing for the
purpose of this study, was performed if clinical results were
unavailable for study use.
For this analysis, we included participants with illness onset
on or after 1 February 2021, for those aged ≥65 years, and
on or after 22 March 2021, for those aged 16–64 years; beginning dates of inclusion in analyses varied by site according
to local COVID-19 vaccination policies for all persons aged
≥65 or ≥16 years (Supplementary Table 1). We determined
vaccination status through participant interviews and verified
vaccination based on participant-provided vaccination record
cards, documentation of vaccination in electronic medical
records, or state immunization information systems. Fully
vaccinated participants were defined as those who received
2 doses of an mRNA vaccine (Pfizer-BioNTech BNT162b2 or
Moderna mRNA-1273) ≥14 days before illness onset [2, 4].
Partially vaccinated participants were defined as those who
received ≥1 dose of an mRNA vaccine ≥14 days before illness onset but who were not fully vaccinated. Those who did
not report vaccine receipt and had no documentation of any
COVID-19 vaccine before illness were defined as unvaccinated. Participants who received their first dose <14 days before illness (n = 100), had been vaccinated with Johnson &
Johnson’s Janssen (JNJ-784367350) vaccine (n = 22), or selfreported vaccine receipt without documentation (n = 35) were
excluded.
For each category of COVID-19 vaccination, VE was calculated as 1 − odds ratio of vaccination among SARS-CoV-2
test-positive participants versus test-negative participants
(controls), using multivariable logistic regression. Models
were adjusted a priori for study site, age in years (continuous), and enrollment period (natural cubic spline with 3 percentile knots of interval between 1 January 2021 and illness
onset date). We evaluated sex, race and Hispanic ethnicity,
and having had a SARS-CoV-2–positive contact as additional
covariates and included race/ethnicity and positive contact
in the final models. We also performed sensitivity analyses
comparing VE using plausible self-report with documented
vaccination, where plausibility was determined by ability to
report credible location of vaccination. Statistical analyses
were conducted using SAS software, version 9.4. This activity was reviewed by the institutional review boards of the
Centers for Disease Control and Prevention (CDC) and other
participating institutions and was conducted consistent with
applicable federal law and CDC policy.

Table 1. Characteristics of Enrolled Participants by Severe Acute
Respiratory Syndrome Coronavirus 2 Status, US Influenza Vaccine
Effectiveness Network, 1 February to 28 May 2021
Participants, No. (Column %)
SARS-CoV-2 Negative
(Controls) (n = 576)

200 (85)

455 (79)

36 (15)

121 (21)

Michigan

87 (37)

55 (10)

Pennsylvania

57 (24)

77 (13)

P
Valuea

Age group, y
16–64
≥65

.06

Study site

Texas

18 (8)

124 (22)

Washington

53 (22)

221 (38)

Wisconsin

21 (9)

99 (17)

145 (61)

408 (71)

91 (39)

168 (29)

52 (23)

49 (9)

4 (2)

46 (8)

<.01

Sex
Female
Male

<.01

Race/ethnicityb
Black nonHispanic
Hispanic
Other nonHispanic

19 (8)

White nonHispanic

156 (68)

405 (71)

No

155 (67)

351 (63)

Yes

78 (33)

209 (37)

147 (62)

517 (90)

89 (38)

59 (10)

No

209 (91)

469 (85)

Yes

20 (9)

85 (15)

No

214 (91)

521 (92)

Yes

20 (9)

48 (8)

<.01

74 (13)

Underlying
conditionc
.42

Contact with
COVID-19 case
No/unknown
Yes

<.01

Healthcare workerd
.06

Prior infectione
.86

Time from illness
onset to specimen collection, d
0–3

114 (48)

305 (53)

4–6

79 (33)

194 (34)

7–10

43 (18)

77 (13)

.19

Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
a
P values calculated with χ2 test, with differences considered statistically significant at
P < .05.
b
Information on race/ethnicity was missing for 7 participants (5 SARS-CoV-2–positive case
patients and 2 test-negative controls).
c
Underlying conditions (eg, heart disease, lung disease, diabetes, cancer, liver or kidney
disease, immune suppression, or high blood pressure) were self-reported, with underlying
condition status missing for 19 participants (3 SARS-CoV-2–positive case patients and 16
test-negative controls) .
d
Work in healthcare settings was self-reported, with data missing for 3 participants; participants <18 years old were not asked this question.
e
Prior infection was self-reported, with prior infection status missing for 9 participants (2
SARS-CoV-2–positive case patients and 7 test-negative controls).
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SARS-CoV-2 Positive
(Cases) (n = 236)

Characteristic

younger adults and adolescents, and thus a higher proportion of
cases may occur in this age group. Second, people with mild and
moderate COVID-19 are rarely hospitalized and are more likely
to seek care in outpatient facilities. Thus, when considering logistics of monitoring VE, planning for enrollment and sample
size, evaluating duration of protection, and assessing protection against variants of concern in real time is more feasible in
outpatient settings. In addition, outpatient networks have the
capability to evaluate possible long-term effects of mild and
moderate COVID-19 through follow-up surveys and extraction
of related postenrollment medical visits and hospitalizations.
The third rationale for monitoring VE against COVID-19
in outpatient settings is that past experiences from the annual influenza vaccination program have demonstrated success of test-negative studies for monitoring VE among people
seeking outpatient medical care for respiratory illness. In turn,
VE studies in outpatient settings can be conducted in a timely
manner and have less potential for confounding than traditional case-control and cohort studies [8]. Thus, implementing
VE studies in outpatient settings to monitor vaccine protection
could be valuable for informing policy decisions, such as community mitigation strategies and strain selection for vaccines or
booster doses.
These results were subject to several limitations. First, because the uptake of Johnson & Johnson’s Janssen vaccine in the
general population was limited during the study period, participants receiving the Janssen vaccine were not included in this
analysis. Including the 22 vaccinated participants who received
the Janssen vaccine (4 case patients and 18 controls) resulted in
similar estimates of VE (Supplementary Table 2). Second, surveillance populations at the study sites are not representative of
the US population, and this analysis did not evaluate VE by race
and Hispanic ethnicity. Additional evaluation of VE among racial/ethnic groups disproportionately affected by the pandemic
and among other specific populations, such as persons with underlying health conditions, are needed.
As a third limitation, because we relied on vaccine documentation to determine vaccination status, we may have missed
unrecorded vaccine doses. However, estimates including selfreported doses, without documentation, showed similar VE
(Supplementary Table 2). Fourth, selection bias may occur in
test-negative studies if vaccinated people were more likely than
unvaccinated people to seek care or agree to participate in the
study, but that would be expected to underestimate VE. Finally,
this analysis measured VE against symptomatic COVID-19
caused by SARS-CoV-2 viruses that circulated during the study
period, before emergence of the delta (B.1.617.2) variant in the
United States. Further enrollment in the US Flu VE Network
will evaluate COVID-19 vaccine protection against delta
(B.1.617.2) and emerging variants.

Table 2. Estimates of Messenger RNA Vaccine Effectiveness Against Laboratory-Confirmed Coronavirus Disease 2019 Among Outpatients, Using Vaccine
Doses Verified by Immunization Documentation
Outpatients, No. Vaccinated/Total (% Vaccinated)

VE (95% CI), %

SARS-CoV-2 Negative (Controls)

Unadjusted

Adjusteda

Full vaccination

17/216 (8)

231/480 (48)

91 (84–95)

91 (83–95)

Partial vaccination

20/219 (9)

96/345 (28)

74 (56–84)

75 (55–87)

Abbreviations: CI, confidence interval; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VE, vaccine effectiveness.
a

VE adjusted for study site, age in years (continuous), enrollment period (natural cubic spline with 3 percentile knots), race/ethnicity, and contact with a SARS-CoV-2–positive person.

As of 29 August 2021, 62% of the US population had received ≥1 dose of a COVID-19 vaccine [15]. A growing
number of VE studies have provided evidence that mRNA
vaccines confer similar protection against COVID-19 in realworld conditions as in clinical trials, reducing risk of infection and related severe outcomes by ≥90% among those fully
vaccinated [1, 2, 12]. In this study, receipt of mRNA vaccines
was associated with prevention of most mild to moderate
COVID-19 in outpatients seeking medical care or testing in
the United States.
Studies should continue to monitor COVID-19 VE against
symptomatic illness over time and against variant SARSCoV-2 viruses to inform vaccination strategies. With the high
VE against mild to moderate COVID-19 observed during the
study period, early community vaccination strategies likely
had a marked impact on disease burden. Efforts to increase
vaccination coverage are warranted as the primary prevention
strategy, in addition to use of masking, social distancing, and
community mitigation strategies for schools, workplaces and
gatherings.
Supplementary Data

Supplementary materials are available at The Journal of Infectious
Diseases online. Consisting of data provided by the authors to
benefit the reader, the posted materials are not copyedited and
are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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